Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections

Detalles Bibliográficos
Autores principales: Orenstein, Robert, Hecht, Gail, Harvey, Adam, Tillotson, Glenn, Khanna, Sahil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Insight Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485881/
https://www.ncbi.nlm.nih.gov/pubmed/37691735
http://dx.doi.org/10.1093/ofid/ofad456
_version_ 1785102882530394112
author Orenstein, Robert
Hecht, Gail
Harvey, Adam
Tillotson, Glenn
Khanna, Sahil
author_facet Orenstein, Robert
Hecht, Gail
Harvey, Adam
Tillotson, Glenn
Khanna, Sahil
author_sort Orenstein, Robert
collection PubMed
description
format Online
Article
Text
id pubmed-10485881
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104858812023-09-09 Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections Orenstein, Robert Hecht, Gail Harvey, Adam Tillotson, Glenn Khanna, Sahil Open Forum Infect Dis Insight Article Oxford University Press 2023-09-08 /pmc/articles/PMC10485881/ /pubmed/37691735 http://dx.doi.org/10.1093/ofid/ofad456 Text en © The Author(s) 2023. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Insight Article
Orenstein, Robert
Hecht, Gail
Harvey, Adam
Tillotson, Glenn
Khanna, Sahil
Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
title Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
title_full Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
title_fullStr Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
title_full_unstemmed Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
title_short Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
title_sort two-year durability of rebyota™ (rbl), a live biotherapeutic for the prevention of recurrent clostridioides difficile infections
topic Insight Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485881/
https://www.ncbi.nlm.nih.gov/pubmed/37691735
http://dx.doi.org/10.1093/ofid/ofad456
work_keys_str_mv AT orensteinrobert twoyeardurabilityofrebyotarblalivebiotherapeuticforthepreventionofrecurrentclostridioidesdifficileinfections
AT hechtgail twoyeardurabilityofrebyotarblalivebiotherapeuticforthepreventionofrecurrentclostridioidesdifficileinfections
AT harveyadam twoyeardurabilityofrebyotarblalivebiotherapeuticforthepreventionofrecurrentclostridioidesdifficileinfections
AT tillotsonglenn twoyeardurabilityofrebyotarblalivebiotherapeuticforthepreventionofrecurrentclostridioidesdifficileinfections
AT khannasahil twoyeardurabilityofrebyotarblalivebiotherapeuticforthepreventionofrecurrentclostridioidesdifficileinfections

Ejemplares similares